Showing 1411-1420 of 1735 results for "".
- New Paper Examines Top 10 Myths About Fitting Soft Contact Lenseshttps://modernod.com/news/new-paper-examines-top-10-myths-about-fitting-soft-contact-lenses/2480598/A new peer-review paper from the Centre for Ocular Research & Education (CORE) seeks to shift persistent views about contact lenses that are no longer accurate based on current evidence. Addressing common myths and mis
- Market Scope: Miami, Philadelphia, and Virginia Beach in Top 10 Markets of Glaucoma Treatment Opportunityhttps://modernod.com/news/market-scope-miami-philadelphia-and-virginia-beach-in-top-10-markets-of-glaucoma-treatment-opportunity/2477291/The metro areas of New York, Los Angeles, Dallas, and Chicago account for 13 percent of the US glaucoma and ocular hypertension population. However, on a per capita share basis, most of the metro areas in Florida stand out for glaucoma disease, driven largely by the state’s high median age. Naple
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- Wills Eye Hospital’s Training in Ophthalmology Voted #1 Top Eye Residency Program in Nationhttps://modernod.com/news/wills-eye-hospitals-training-in-ophthalmology-voted-1-top-eye-residency-program-in-nation/2479623/The Wills Eye at Jefferson Residency Program in Philadelphia has been voted the #1 medical education training program in ophthalmology in the nation, according to Doximity.com. The Wills Eye Hospital faculty serve as the department of Ophthalmology at Thomas Jefferson
- 2018 Best of Eyetubehttps://modernod.com/news/2018-best-of-eyetube/2476238/Cataract & Refractive Surgery Today (CRST) has compiled the best content of 2018 from Eyetube.net, the leading video resource for ophthalmologists. Below are descriptions of a few of the top videos. To view all of the videos and their descriptions, click
- American Academy of Ophthalmology Urges Members to Immediately Stop Routine Surgical and In-Office Visitshttps://modernod.com/news/american-academy-of-ophthalmology-urges-members-to-immediately-stop-routine-surgical-and-in-office-visits/2477412/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) stated that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately. The statement posted on the AAO website reads: “We now live and practice in a critically di
- Prevent Blindness Says West Virginia State House Bill Would Imperil Children’s Visionhttps://modernod.com/news/prevent-blindness-says-west-virginia-state-house-bill-would-imperil-childrens-vision/2482738/Prevent Blindness published a letter on its website Tuesday calling on the West Virginia State House to reject
- NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.comhttps://modernod.com/news/novabay-pharmaceuticals-announces-the-availability-of-kn95-disposable-masks-on-avenova-com/2477457/NovaBay Pharmaceuticals announced the availability of KN95 disposable air filter masks on the company’s website
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis-1/2481676/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for t
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis/2479122/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpo